Oncology at Universitaetsklinikum Erlangen AöR
The clinical research here is centered on neoplasms, with studies focused on cancer and large B-cell lymphoma. These trials are designed to explore new treatment options and assess how well emerging therapies perform in people with blood-related cancers.
- Evaluating new treatment strategies for large B-cell lymphoma
- Comparing the effectiveness of combination approaches in cancer care
- Assessing safety and tolerability of oncology treatments
With 5 trials and 81 investigators contributing, Medizinische Klinik 5 supports focused research aimed at improving outcomes for patients with difficult-to-treat malignancies.
Hematologic Cancer Research
The site is also active in studies of blood cancers, especially large B-cell lymphoma, where researchers are testing whether new combinations can improve disease control and extend the time before the disease worsens.
- Testing combination therapy for newly diagnosed large B-cell lymphoma
- Measuring treatment effectiveness through progression-free survival
- Supporting development of more effective lymphoma therapies
This work reflects a strong clinical focus on refining care for patients with aggressive hematologic malignancies.
Therapy Continuation and Safety Studies
Another part of the research portfolio involves follow-up studies that look at whether ongoing treatment remains safe and appropriate for patients who have already received therapy in other studies.
- Continuing darolutamide treatment in eligible participants
- Monitoring treatment safety over time
- Supporting long-term care decisions in oncology
At Universitaetsklinikum Erlangen AöR, these studies help build a clearer picture of how cancer treatments perform beyond initial use, with attention to both benefit and safety.
